Nirsevimab immunization's real‐world effectiveness in preventing severe bronchiolitis: A test‐negative case–control study
Pediatric Allergy and Immunology · 2024
DOI: 10.1111/pai.14175 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Allergy and Immunology, 2024. Verfasst von Marta Agüera und 19 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics Department, Hospital Sant Joan de Déu, Barcelona, Spain. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background Several clinical trials have shown that nirsevimab, an antibody targeting the respiratory syncytial virus (RSV), reduces RSV bronchiolitis requiring admission. In 2023–2024, Catalonia and Andorra adopted immunization strategies for children
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatrics Department, Hospital Sant Joan de Déu, Barcelona, Spain.
- Pediatric Infectious Diseases and Microbiome Research Group, Institut de Recerca Sant Joan de Déu, Spain.
- Departament de Cirurgia i Especialitats Medicoquirúrgiques, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
- Department of Medicine, School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain.
- Pediatrics Department, Hospital General de Catalunya, Barcelona, Spain.
- Pediatric Intensive Care Unit Department, Hospital Sant Joan de Déu, Barcelona, Spain.
ORCID-Profile: Marta Agüera, Aleix Soler-Garcia, Pere Sala-Castellví, Gemma Pons, Daniel Penela-Sánchez, Cristina Esteva, Mariona-F de-Sevilla, Juan-José García-García, Pedro Brotons, Albert Balaguer, Iolanda Jordan, Carmen Muñoz-Almagro, Cristian Launes
Zitieren
APA
Agüera, M., Soler-Garcia, A., Alejandre, C., Moussalam-Merino, S., Sala-Castellví, P., Pons, G., Penela-Sánchez, D., González-Grado, C., Alsina-Rossell, J., Climent, C., Esteva, C., Fortuny, C., de-Sevilla, M. F., García-García, J. J., Brotons, P., Balaguer, A., Estrada, J., Jordan, I., Muñoz-Almagro, C., & Launes, C. (2024). Nirsevimab immunization's real‐world effectiveness in preventing severe bronchiolitis: A test‐negative case–control study. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.14175
Vancouver
Agüera M, Soler-Garcia A, Alejandre C, Moussalam-Merino S, Sala-Castellví P, Pons G, et al. Nirsevimab immunization's real‐world effectiveness in preventing severe bronchiolitis: A test‐negative case–control study. Pediatric Allergy and Immunology. 2024. doi:10.1111/pai.14175
BibTeX
@article{Agera2024,
author = {Agüera, Marta and Soler-Garcia, Aleix and Alejandre, Carme and Moussalam-Merino, Sara and Sala-Castellví, Pere and Pons, Gemma and Penela-Sánchez, Daniel and González-Grado, Carla and Alsina-Rossell, Judit and Climent, Carme and Esteva, Cristina and Fortuny, Clàudia and de-Sevilla, Mariona-F and García-García, Juan-José and Brotons, Pedro and Balaguer, Albert and Estrada, Josep and Jordan, Iolanda and Muñoz-Almagro, Carmen and Launes, Cristian},
title = {Nirsevimab immunization's real‐world effectiveness in preventing severe bronchiolitis: A test‐negative case–control study},
journal = {Pediatric Allergy and Immunology},
year = {2024},
doi = {10.1111/pai.14175}
}
EUVIMED